文献速递肝胆胰外科围术期管理与 ERAS

达芬奇Xi机器人辅助胰十二指肠切除术与开腹手术的病例匹配成本分析

Robot-assisted pancreatoduodenectomy with the da Vinci Xi: can the costs of advanced technology be offset by clinical advantages? A case-matched cost analysis versus open approach.
PubMed 文献 · Surg Endosc · 2021-10-27

该回顾性病例匹配成本分析比较了同一术者2011至2020年间20例达芬奇Xi机器人辅助胰十二指肠切除术(RPD)与40例开腹胰十二指肠切除术(OPD)的围术期数据与直接成本。结果显示RPD组住院中位时间显著更短(10天 vs 16天,p=0.001),耗材成本显著更高(€6149.2 vs €1267.4,p<0.001),但住院成本显著更低(€5231.6 vs €8180,p=0.001),总体可变成本(OVCs)两组无显著差异(€13,483.4 vs €11,879.8,p=0.076)。结论认为先进技术的高成本可被临床优势部分抵消。

要点

  • RPD组住院中位时间显著短于OPD组(10天 vs 16天,p=0.001)。
  • RPD组耗材成本显著更高,但住院成本显著更低。
  • 两组总体可变成本无显著差异(p=0.076)。

核心结论

  • 机器人手术因购置和维护成本更高而更昂贵,但RPD的耗材高成本被住院时间缩短带来的住院成本降低所部分抵消。
  • 由于手术时间相似,人员成本无差异,最终两种技术的总体可变成本不再有显著差异。
  • 先进技术的高成本可被临床优势部分补偿,尤其在高容量多学科中心。

研究设计与样本

  • 回顾性病例匹配成本分析,纳入2011年1月至2020年12月同一术者在高容量多学科中心实施的20例RPD和194例OPD。
  • 按1:2匹配RPD组与OPD组,得到20例Xi-RPD组和40例OPD组,比较围术期数据与总体成本(含总体可变成本和固定成本)。

主要发现

  • 平均手术时间无差异:Xi-RPD组428分钟 vs OPD组404分钟,p=0.212。
  • 住院中位时间Xi-RPD组显著更低:10天 vs 16天,p=0.001。
  • 耗材成本Xi-RPD组显著更高:€6149.2 vs €1267.4,p<0.001。
  • 住院成本Xi-RPD组显著更低:€5231.6 vs €8180,p=0.001。
  • 总体可变成本无显著差异:Xi-RPD组€13,483.4 vs OPD组€11,879.8,p=0.076。

临床怎么用

  • 在高容量机器人及胰腺手术中心,RPD虽耗材成本更高,但可通过缩短住院时间降低住院成本,使总体可变成本与OPD无显著差异。
  • 成本决策需综合考虑耗材、住院天数及人员成本,而非仅关注单项费用。

局限性

  • 回顾性研究设计,样本量有限(RPD 20例,OPD 40例),结论需进一步研究证实。
  • 成本数据来自单中心高容量多学科中心,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Robot-assisted pancreatoduodenectomy (RPD) has shown some advantages over open pancreatoduodenectomy (OPD) but few studies have reported a cost analysis between the two techniques. We conducted a structured cost-analysis comparing pancreatoduodenectomy performed with the use of the da Vinci Xi, and the traditional open approach, and considering healthcare direct costs associated with the intervention and the short-term post-operative course. MATERIALS AND METHODS: Twenty RPD and 194 OPD performed between January 2011 and December 2020 by the same operator at our high-volume multidisciplinary center for robot-assisted surgery and for pancreatic surgery, were retrospectively analyzed. Two comparable groups of 20 patients (Xi-RPD-group) and 40 patients (OPD-group) were obtained matching 1:2 the RPD-group with the OPD-group. Perioperative data and overall costs, including overall variable costs (OVCs) and fixed costs, were compared. RESULTS: No difference was reported in mean operative time: 428 min for Xi-RPD-group versus 404 min for OPD, p = 0.212. The median overall length of hospital stay was significantly lower in the Xi-RPD-group: 10 days versus 16 days, p = 0.001. In the Xi-RPD-group, consumable costs were significantly higher (€6149.2 versus €1267.4, p < 0.001), while hospital stay costs were significantly lower: €5231.6 versus €8180 (p = 0.001). No significant differences were found in terms of OVCs: €13,483.4 in Xi-RPD-group versus €11,879.8 in OPD-group (p = 0.076). CONCLUSIONS: Robot-assisted surgery is more expensive because of higher acquisition and maintenance costs. However, although RPD is associated to higher material costs, the advantages of the robotic system associated to lower hospital stay costs and the absence of difference in terms of personnel costs thanks to the similar operative time with respect to OPD, make the OVCs of the two techniques no longer different. Hence, the higher costs of advanced technology can be partially compensated by clinical advantages, particularly within a high-volume multidisciplinary center for both robot-assisted and pancreatic surgery. These preliminary data need confirmation by further studies.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Di Franco G, Lorenzoni V, Palmeri M, et al. Robot-assisted pancreatoduodenectomy with the da Vinci Xi: can the costs of advanced technology be offset by clinical advantages? A case-matched cost analysis versus open approach. Surg Endosc. 2021. PMID: 34708294. doi:10.1007/s00464-021-08793-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。